Drugs / Relamorelin
Relamorelin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02357420 | Jan 2015 → Jun 2016 | diabetes mellitus, gastroparesis | Allergan | Completed | Missed primary |
| Phase 35 trials | ||||||
| Phase 3 | NCT03786380 | Dec 2018 → Oct 2020 | gastroparesis | Allergan | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03426345 | Feb 2018 → Jul 2020 | diabetes mellitus, gastroparesis | Allergan | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03383146 | Feb 2018 → Nov 2020 | diabetes mellitus, gastroparesis | Allergan | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03420781 | Jan 2018 → Oct 2020 | diabetes mellitus, gastroparesis | Allergan | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03285308 | Sep 2017 → Jul 2020 | diabetes mellitus, gastroparesis | Allergan | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02466711 Comparator | Jun → Aug 2015 | intestinal dysmotility syndrome | Motus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Relamorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02357420 ↗ |
| Known as | BIM-28131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297525 ↗ |
| Known as | Relamorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297525 ↗ |
| Known as | Relamoreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297525 ↗ |
| Action | Activate | “a selective, prokinetic agonist of ghrelin” PMID 28760384 ↗ Jul 20171“Ghrelin receptor agonist” CHEMBL4297525 ↗ |
| Modality | Peptide | “a pentapeptide ghrelin receptor agonist” PMID 32301137 ↗ Apr 2020 |
| Route | Subcutaneous | “Study drug (relamorelin and placebo) will be administered subcutaneously in a blinded fashion.” NCT02357420 ↗ |
| Target | GHSR | “Ghrelin receptor agonist” CHEMBL4297525 ↗ |